CMS Proposes New Deadlines for Prior Authorizations for Drugs

Why It Matters

By tightening PA timelines for drugs, the rule aims to reduce administrative delays, improve patient access, and generate cost savings for providers and payers, while increasing transparency across the health‑insurance market.

Key Takeaways

• CMS proposes electronic prior auth for drugs with 72‑hour decision window
• Medicaid and CHIP insurers must respond within 24 hours for drug requests
• ACA plans face up to 72 hours for standard drug prior auth
• Insurers must publicly report drug prior‑auth approval and denial rates
• Commercial plans remain outside the proposed deadline requirements

Pulse Analysis

The CMS proposal builds on the Biden administration’s earlier effort to curb prior‑authorization bottlenecks, extending those timelines to prescription drugs—a high‑volume segment that has long been a blind spot. By requiring electronic prior authorizations and setting clear turnaround windows—24 hours for Medicaid and CHIP, 72 hours for standard ACA requests, and 24 hours for expedited cases—CMS seeks to streamline the approval process and reduce the paperwork burden that clinicians routinely cite as a barrier to timely care.

Transparency is a second pillar of the rule. Insurers will be obligated to publish detailed metrics on drug prior‑authorization outcomes, including approval rates, denial reasons, appeal results, and decision times. The mandate to disclose API usage will also let regulators monitor interoperability across payer systems, fostering a more data‑driven oversight environment. For providers, these disclosures could illuminate patterns of unnecessary denials and help negotiate more efficient workflows, while patients may benefit from faster access to needed medications.

However, the proposal stops short of covering commercial employer‑sponsored plans, which serve the majority of Americans. Industry groups argue that voluntary reductions—already showing an 11 % drop in prior‑auth volume—may offset the need for regulatory mandates in that segment. Still, the rule’s compliance deadline of October 2027 gives insurers a multi‑year horizon to upgrade technology and adjust processes, balancing the upfront costs of new data‑exchange standards against projected savings from fewer appeals and reduced administrative overhead.